Press Releases

« Back
Printer Friendly Version View printer-friendly version
Download PDF Download PDF
Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations

WATERTOWN, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced the following upcoming clinical presentations:

European Society of Gene & Cell Therapy (ESGCT 2017)                                      
  Title: Anc80 and SVP-Rapamycin: A Novel Approach to AAV Gene Therapy for Methylmalonic Acidemia  
  Type: Poster Presentation  
  Location: Berlin, Germany  
  Date: October 18, 2017  
 
  Title: Development of a Novel Adeno-Associated Viral Vector in Combination with Tolerogenic Nanoparticles for the Treatment of Ornithine Transcarbamylase Deficiency  
  Type: Poster Presentation  
  Location: Berlin, Germany  
  Date: October 18, 2017  
 
SMI’s Orphan Drugs and Rare Diseases Conference  
  Title: Improving the Efficacy and Safety Profile of Biologic Therapeutic Candidates for Orphan and Rare Diseases by Addressing Product Immunogenicity                      
  Type: Oral Presentation  
  Location: London, England  
  Date: October 18, 2017 at 1:15 p.m. local time  
 
19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017)  
  Title: Design and Early Clinical Development of SEL-212, a Non-Immunogenic Pegylated Uricase for the Treatment of Chronic Severe Gout                  
  Type: Oral Presentation  
  Location:Dubai, U.A.E.  
  Date: October 20, 2017 at 11:20 a.m. local time  
 
Ninth Annual Immunogenicity & Bioassay Summit  
  Title: Clinical Development of SEL-212: Use of Tolerogenic Nanoparticles to Mitigate Immunogenicity Against an Enzyme Therapy to Treat Severe Gout                    
  Type: Oral Presentation  
  Location: Washington, D.C.  
  Date: October 26, 2017 at 3:25 p.m. local time  
 
American College of Rheumatology Annual Meeting (ACR 2017)  
  Title: Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVP-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-Drug Antibodies                                      
  Type: Poster Presentation  
  Location: San Diego, CA  
  Date: November 7, 2017  
       

Selecta plans to report updated patient data from the ongoing Phase 2 trial of its lead product candidate, SEL-212, in conjunction with its ACR 2017 presentation on Tuesday, November 7, 2017.

About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s oncology candidate, SEL-403, leverages a potent recombinant immunotoxin (LMB-100) that is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates, SEL-302 and SEL-313, are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.

Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the progress of the Phase 2 clinical program of SEL-212, the potential of SEL-212 to treat severe gout patients and resolve their debilitating symptoms, the company’s ability to unlock the full potential of biologic therapies, the ability of SEL-212 to mitigate immunogenicity and/or enable the sustained reduction of serum uric acid levels for the treatment of chronic severe gout, the ability of the company’s SVP platform to improve the efficacy and safety of biologics by addressing immunogenicity, the potential applications for products utilizing the SVP platform in areas such as enzyme therapy, gene therapy, oncology therapy, vaccines and treatments for allergies and autoimmune diseases, the potential of the company’s two gene therapy product candidates to enable repeat administration and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including their uncertain outcomes, the unproven approach of the company’s SVP technology, undesirable side effects of the company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, substantial fluctuation in the price of its common stock, a significant portion of the company’s total outstanding shares have recently become eligible to be sold into the market, and other important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on August 11, 2017, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Contact Information:
Jason Fredette
Selecta Biosciences, Inc.
617-231-8078
jfredette@selectabio.com

Primary Logo

Selecta Biosciences

Back to Top